This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
by Zacks Equity Research
Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler.
Here's Why Alexion Pharma (ALXN) Stock is Sinking Today
by Madeleine Johnson
On Tuesday, shares of Alexion Pharmaceuticals Inc. (ALXN) are sinking, down over about 8.5% in mid-morning trading after the company announced a series of changes to its executive team.
Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.
Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab
by Zacks Equity Research
Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.
Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported first-quarter 2017 earnings of 31 cents per share (including the impact of stock-based compensation expenses), down 32.5% from the year-ago figure.
Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat
by Zacks Equity Research
Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.
AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2017 loss of 12 cents per share, narrower than the Zacks Consensus Estimate as well as year-ago loss of 13 cents.
Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.
Is Endo (ENDP) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report first-quarter 2017 results on May 9, before the opening bell.
Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss
by Zacks Equity Research
Ophthotech Corporation (OPHT) reported first-quarter 2017 loss of $1.20 per share, narrower than the Zacks Consensus Estimate of a loss of $1.31 but wider than the year-ago loss of $1.03
Can Ligand (LGND) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
We expect Conatus Pharmaceuticals Inc. (CNAT) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.
Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .
The Medicines Company (MDCO) Q1 Loss Wider Than Expected
by Zacks Equity Research
The Medicines Company (MDCO) reported loss $1.44 per share, wider than the Zacks Consensus Estimate of a loss of $1.13.
What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.
Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales
by Zacks Equity Research
Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.
Key Factors to Look Out for in Celgene's (CELG) Q1 Results
by Arpita Dutt
Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.
Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS
by Zacks Equity Research
As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.
What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%.
Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.
Allergan (AGN) Collaborates with Novartis to Treat NASH
by Zacks Equity Research
Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis
Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.
Novartis (NVS) Up 7.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Novartis (NVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.